APOGEE THERAPEUTICS, INC.

Analyst Reco. Apogee Therapeutics, Inc.

Equities

APGE

US03770N1019

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
53.3 ^USD	-1.30%		+3.98%	+90.77%

May. 13	Apogee Therapeutics' Q1 Net Loss Widens	MT
May. 13	Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target	May. 10	MT
Jefferies Adjusts Price Target on Apogee Therapeutics to $75 From $37, Maintains Buy Rating	Mar. 06	MT
Wedbush Raises Apogee Therapeutics' PT to $87 From $40 After Reporting Initial Safety, PK Results From Phase 1 Trial of APG777; Maintains Outperform Rating	Mar. 05	MT
Guggenheim Adjusts Apogee Therapeutics' Price Target to $44 From $29, Maintains Buy Rating	Jan. 03	MT
BTIG Initiates Apogee Therapeutics With Buy Rating, Price Target is $43	Dec. 20	MT
TD Cowen Initiates Apogee Therapeutics With Outperform Rating	23-08-08	MT
Stifel Initiates Apogee Therapeutics With Buy Rating, $34 Price Target	23-08-08	MT
Jefferies Initiates Apogee Therapeutics With Buy Rating, $29 Price Target	23-08-08	MT
Guggenheim Starts Apogee Therapeutics With Buy Rating, $29 Price Target	23-08-08	MT
Wedbush Initiates Apogee Therapeutics at Outperform With $40 Price Target	23-08-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW